AAM Statement on Biden’s Executive Orders to Strengthen America’s COVID Response | Association for Accessible Medicines
AAM All Access Podcast - Featuring AAM CEO Dan Leonard and Apotex President and CEO Jeff Watson

AAM Statement on Biden’s Executive Orders to Strengthen America’s COVID Response

WASHINGTON, DC (January 21, 2020) — The Association for Accessible Medicines (AAM) strongly endorses the Biden administration’s executive orders to strengthen America’s response to the COVID pandemic. Generic medicines have been instrumental in treating COVID patients with severe conditions, serving as a bridge until the COVID vaccines are widely available. AAM’s members are ready to partner with the Biden administration to ensure reliable and predictable access to these vital therapies.

We also strongly support the Administration’s efforts to strengthen the U.S. pharmaceutical supply chain and domestic manufacturing. More than 60 billion doses of generic medicines are made each year in the U.S., but more is possible with the right incentives in place. By ensuring that more essential medicines are produced in the United States, American patients and our health care system will be better prepared to withstand any future pandemics, natural disasters or global supply chain disruptions. AAM’s Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain describes specific incentives to facilitate greater production of essential medicines in the U.S. and aligns closely with the Biden administration’s proposed approach.

 

MEDIA CONTACT:
Rachel Schwartz
202.249.7147 

 

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending. 

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.